GLP-1 Receptor Agonist Market Size, Share, & Industry Analysis Report: By Route of Administration (Parenteral and Oral), By Product, By Application, By Distribution Channel, and By Region – Market Forecast, 2025–2034
Description
The GLP-1 receptor agonists market size is expected to reach USD 257.12 billion by 2034, according to a new study by Polaris Market Research. The report “GLP-1 Receptor Agonist Market Share, Size, & Industry Analysis Report: By Route of Administration (Parenteral and Oral), By Product, By Application, By Distribution Channel, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
GLP-1 receptor agonists are therapeutic agents that improve the body’s natural insulin response while simultaneously suppressing appetite and delaying gastric troubles. The increasing preference for dual-purpose treatments that address both type 2 diabetes and obesity within a single therapeutic framework boosts growth opportunities. This dual action improves clinical outcomes and offers a cost-effective and simplified approach to managing comorbid conditions. The versatility of GLP-1 receptor agonists continues to attract broader clinical adoption across multiple care settings as healthcare systems worldwide seek integrated solutions to tackle metabolic disorders.
The GLP-1 receptor agonist market is driven by the evolution of drug delivery technologies aimed at improving patient observation and convenience. The shift toward less invasive, user-friendly formulations, such as oral tablets and auto injectors, has made these therapies more accessible and appealing to a larger patient demographic. These advancements are reducing treatment fatigue associated with frequent dosing and improving the overall patient experience. As a result, pharmaceutical companies are investing especially in delivery innovation to differentiate their offerings in a competitive market landscape and meet growing patient expectations.
GLP-1 Receptor Agonist Market Report Highlights
In terms of product, the ozempic segment led the GLP-1 receptor agonist market in 2024, attributed to its proven clinical efficiency, strong brand awareness, and broad utilization in type 2 diabetes treatment protocols.
Based on application, the obesity segment is poised for expansion during the forecast period, fueled by increasing global obesity rates and growing demand for advanced pharmacotherapies.
In 2024, the North America GLP-1 receptor agonist market accounted for the largest revenue share, owing to high metabolic disorder prevalence, early uptake of innovative therapies, and robust healthcare systems.
Asia Pacific is anticipated to exhibit the highest growth rate during the forecast period, propelled by surging diabetes and obesity incidence in key regional markets.
A few global key market players include Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Genentech, Inc.; Hanmi Pharm.Co., Ltd.; Innovent; Lilly; Novo Nordisk A/S; Pfizer Inc.; and Sanofi.
Polaris Market Research has segmented the GLP-1 receptor agonist market report on the basis of route of administration, product, application, distribution channel, and region:
By Product Outlook (Revenue, USD Billion, 2020–2034)
Ozempic
Trulicity
Mounjaro
Wegovy
Rybelsus
Saxenda
Victoza
Zepbound
Others
By Application Outlook (Revenue, USD Billion, 2020–2034)
Type 2 Diabetes Mellitus
Obesity
By Route of Administration Outlook (Revenue, USD Billion, 2020–2034)
Parenteral
Oral
By Distribution Channel Outlook (Revenue, USD Billion, 2020–2034)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Regional Outlook (Revenue, USD Billion, 2020–2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
GLP-1 receptor agonists are therapeutic agents that improve the body’s natural insulin response while simultaneously suppressing appetite and delaying gastric troubles. The increasing preference for dual-purpose treatments that address both type 2 diabetes and obesity within a single therapeutic framework boosts growth opportunities. This dual action improves clinical outcomes and offers a cost-effective and simplified approach to managing comorbid conditions. The versatility of GLP-1 receptor agonists continues to attract broader clinical adoption across multiple care settings as healthcare systems worldwide seek integrated solutions to tackle metabolic disorders.
The GLP-1 receptor agonist market is driven by the evolution of drug delivery technologies aimed at improving patient observation and convenience. The shift toward less invasive, user-friendly formulations, such as oral tablets and auto injectors, has made these therapies more accessible and appealing to a larger patient demographic. These advancements are reducing treatment fatigue associated with frequent dosing and improving the overall patient experience. As a result, pharmaceutical companies are investing especially in delivery innovation to differentiate their offerings in a competitive market landscape and meet growing patient expectations.
GLP-1 Receptor Agonist Market Report Highlights
In terms of product, the ozempic segment led the GLP-1 receptor agonist market in 2024, attributed to its proven clinical efficiency, strong brand awareness, and broad utilization in type 2 diabetes treatment protocols.
Based on application, the obesity segment is poised for expansion during the forecast period, fueled by increasing global obesity rates and growing demand for advanced pharmacotherapies.
In 2024, the North America GLP-1 receptor agonist market accounted for the largest revenue share, owing to high metabolic disorder prevalence, early uptake of innovative therapies, and robust healthcare systems.
Asia Pacific is anticipated to exhibit the highest growth rate during the forecast period, propelled by surging diabetes and obesity incidence in key regional markets.
A few global key market players include Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Genentech, Inc.; Hanmi Pharm.Co., Ltd.; Innovent; Lilly; Novo Nordisk A/S; Pfizer Inc.; and Sanofi.
Polaris Market Research has segmented the GLP-1 receptor agonist market report on the basis of route of administration, product, application, distribution channel, and region:
By Product Outlook (Revenue, USD Billion, 2020–2034)
Ozempic
Trulicity
Mounjaro
Wegovy
Rybelsus
Saxenda
Victoza
Zepbound
Others
By Application Outlook (Revenue, USD Billion, 2020–2034)
Type 2 Diabetes Mellitus
Obesity
By Route of Administration Outlook (Revenue, USD Billion, 2020–2034)
Parenteral
Oral
By Distribution Channel Outlook (Revenue, USD Billion, 2020–2034)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Regional Outlook (Revenue, USD Billion, 2020–2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
129 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global GLP-1 Market Insights
- 4.1. GLP-1 Market – Material Snapshot
- 4.2. GLP-1 Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising prevalence of type 2 diabetes globally
- 4.2.1.2. Increasing rates of obesity and related metabolic disorders
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High cost of GLP-1 drugs and affordability challenges
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. GLP-1 Market Material Trends
- 4.6. Value Chain Analysis
- 5. Global GLP-1 Market, by Type of Molecule
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global GLP-1 Market, by Type of Molecule, 2020–2034 (USD Billion)
- 5.3. Biologics
- 5.3.1. Global GLP-1 Market, by Biologics, by Region, 2020–2034 (USD Billion)
- 5.4. Small Molecules
- 5.4.1. Global GLP-1 Market, by Small Molecules, by Region, 2020–2034 (USD Billion)
- 6. Global GLP-1 Market, by Active Compound Used
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global GLP-1 Market, by Active Compound Used, 2020–2034 (USD Billion)
- 6.3. Dulaglutide
- 6.3.1. Global GLP-1 Market, by Dulaglutide, by Region, 2020–2034 (USD Billion)
- 6.4. Liraglutide
- 6.4.1. Global GLP-1 Market, by Liraglutide, by Region, 2020–2034 (USD Billion)
- 6.5. Orforglipron
- 6.5.1. Global GLP-1 Market, by Orforglipron, by Region, 2020–2034 (USD Billion)
- 6.6. Retatrutide
- 6.6.1. Global GLP-1 Market, by Retatrutide, by Region, 2020–2034 (USD Billion)
- 6.7. Semaglutide
- 6.7.1. Global GLP-1 Market, by Semaglutide, by Region, 2020–2034 (USD Billion)
- 6.8. Survodutide
- 6.8.1. Global GLP-1 Market, by Survodutide, by Region, 2020–2034 (USD Billion)
- 6.9. Tirzepatide
- 6.9.1. Global GLP-1 Market, by Tirzepatide, by Region, 2020–2034 (USD Billion)
- 6.10. Other Active Compounds
- 6.10.1. Global GLP-1 Market, by Other Active Compounds, by Region, 2020–2034 (USD Billion)
- 7. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 7.3. Long-acting GLP-1 Agonist
- 7.3.1. Global GLP-1 Market, by Long-acting GLP-1 Agonist, by Region, 2020-2034 (USD Billion)
- 7.4. Short-acting GLP-1 Agonist
- 7.4.1. Global GLP-1 Market, by Short-acting GLP-1 Agonist, by Region, 2020-2034 (USD Billion)
- 8. Global GLP-1 Market, by Route of Administration
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.3. Oral
- 8.3.1. Global GLP-1 Market, by Oral, by Region, 2020-2034 (USD Billion)
- 8.4. Parenteral
- 8.4.1. Global GLP-1 Market, by Parenteral, by Region, 2020-2034 (USD Billion)
- 9. Global GLP-1 Market, by Target Indication
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Global GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 9.3. ALZHEIMER’S DISEASE
- 9.3.1. Global GLP-1 Market, by ALZHEIMER’S DISEASE, 2020-2034 (USD Billion)
- 9.4. Non-Alcoholic Steatohepatitis
- 9.4.1. Global GLP-1 Market, by Non-Alcoholic Steatohepatitis, 2020-2034 (USD Billion)
- 9.5. Obesity
- 9.5.1. Global GLP-1 Market, by Obesity, 2020-2034 (USD Billion)
- 9.6. Sleep Apnea
- 9.6.1. Global GLP-1 Market, by Sleep Apnea, 2020-2034 (USD Billion)
- 9.7. Type 2 Diabetes
- 9.7.1. Global GLP-1 Market, by Type 2 Diabetes, 2020-2034 (USD Billion)
- 10. Global GLP-1 Market, by Geography
- 10.1. Key Findings
- 10.2. Introduction
- 10.2.1. GLP-1 Market Assessment, By Geography, 2020-2034 (USD Billion)
- 10.3. GLP-1 Market – North America
- 10.3.1. North America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.3.2. North America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.3.3. North America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.3.4. North America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.3.5. North America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.3.6. GLP-1 Market – US
- 10.3.6.1. US: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.3.6.2. US: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.3.6.3. US: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.3.6.4. US: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.3.6.5. US: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.3.7. GLP-1 Market – Canada
- 10.3.7.1. Canada: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.3.7.2. Canada: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.3.7.3. Canada: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.3.7.4. Canada: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.3.7.5. Canada: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4. GLP-1 Market – Europe
- 10.4.1. Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.2. Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.3. Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.4. Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.5. Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.6. GLP-1 Market – UK
- 10.4.6.1. UK: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.6.2. UK: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.6.3. UK: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.6.4. UK: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.6.5. UK: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.7. GLP-1 Market – France
- 10.4.7.1. France: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.7.2. France: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.7.3. France: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.7.4. France: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.7.5. France: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.8. GLP-1 Market – Germany
- 10.4.8.1. Germany: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.8.2. Germany: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.8.3. Germany: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.8.4. Germany: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.8.5. Germany: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.9. GLP-1 Market – Italy
- 10.4.9.1. Italy: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.9.2. Italy: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.9.3. Italy: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.9.4. Italy: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.9.5. Italy: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.10. GLP-1 Market – Spain
- 10.4.10.1. Spain: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.10.2. Spain: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.10.3. Spain: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.10.4. Spain: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.10.5. Spain: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.11. GLP-1 Market – Netherlands
- 10.4.11.1. Netherlands: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.11.2. Netherlands: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.11.3. Netherlands: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.11.4. Netherlands: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.11.5. Netherlands: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.12. GLP-1 Market – Russia
- 10.4.12.1. Russia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.12.2. Russia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.12.3. Russia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.12.4. Russia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.12.5. Russia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.4.13. GLP-1 Market – Rest of Europe
- 10.4.13.1. Rest of Europe: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.4.13.2. Rest of Europe: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.4.13.3. Rest of Europe: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.4.13.4. Rest of Europe: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.4.13.5. Rest of Europe: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5. GLP-1 Market – Asia Pacific
- 10.5.1. Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.2. Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.3. Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.4. Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.5. Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.6. GLP-1 Market – China
- 10.5.6.1. China: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.6.2. China: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.6.3. China: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.6.4. China: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.6.5. China: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.7. GLP-1 Market – India
- 10.5.7.1. India: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.7.2. India: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.7.3. India: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.7.4. India: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.7.5. India: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.8. GLP-1 Market – Malaysia
- 10.5.8.1. Malaysia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.8.2. Malaysia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.8.3. Malaysia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.8.4. Malaysia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.8.5. Malaysia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.9. GLP-1 Market – Japan
- 10.5.9.1. Japan: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.9.2. Japan: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.9.3. Japan: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.9.4. Japan: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.9.5. Japan: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.10. GLP-1 Market – Indonesia
- 10.5.10.1. Indonesia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.10.2. Indonesia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.10.3. Indonesia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.10.4. Indonesia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.10.5. Indonesia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.11. GLP-1 Market – South Korea
- 10.5.11.1. South Korea: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.11.2. South Korea: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.11.3. South Korea: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.11.4. South Korea: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.11.5. South Korea: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.12. GLP-1 Market – Australia
- 10.5.12.1. Australia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.12.2. Australia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.12.3. Australia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.12.4. Australia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.12.5. Australia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.5.13. GLP-1 Market – Rest of Asia Pacific
- 10.5.13.1. Rest of Asia Pacific: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.5.13.2. Rest of Asia Pacific: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.5.13.3. Rest of Asia Pacific: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.5.13.4. Rest of Asia Pacific: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.5.13.5. Rest of Asia Pacific: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6. GLP-1 Market – Middle East & Africa
- 10.6.1. Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.6.2. Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.6.3. Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.6.4. Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.6.5. Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.6. GLP-1 Market – Saudi Arabia
- 10.6.6.1. Saudi Arabia: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.6.6.2. Saudi Arabia: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.6.6.3. Saudi Arabia: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.6.6.4. Saudi Arabia: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.6.6.5. Saudi Arabia: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.7. GLP-1 Market – UAE
- 10.6.7.1. UAE: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.6.7.2. UAE: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.6.7.3. UAE: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.6.7.4. UAE: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.6.7.5. UAE: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.8. GLP-1 Market – Israel
- 10.6.8.1. Israel: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.6.8.2. Israel: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.6.8.3. Israel: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.6.8.4. Israel: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.6.8.5. Israel: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.9. GLP-1 Market – South Africa
- 10.6.9.1. South Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.6.9.2. South Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.6.9.3. South Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.6.9.4. South Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.6.9.5. South Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.6.10. GLP-1 Market – Rest of Middle East & Africa
- 10.6.10.1. Rest of Middle East & Africa: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.6.10.2. Rest of Middle East & Africa: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.6.10.3. Rest of Middle East & Africa: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.6.10.4. Rest of Middle East & Africa: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.6.10.5. Rest of Middle East & Africa: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7. GLP-1 Market – Latin America
- 10.7.1. Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.7.2. Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.7.3. Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.7.4. Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.7.5. Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7.6. GLP-1 Market – Mexico
- 10.7.6.1. Mexico: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.7.6.2. Mexico: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.7.6.3. Mexico: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.7.6.4. Mexico: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.7.6.5. Mexico: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7.7. GLP-1 Market – Brazil
- 10.7.7.1. Brazil: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.7.7.2. Brazil: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.7.7.3. Brazil: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.7.7.4. Brazil: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.7.7.5. Brazil: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7.8. GLP-1 Market – Argentina
- 10.7.8.1. Argentina: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.7.8.2. Argentina: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.7.8.3. Argentina: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.7.8.4. Argentina: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.7.8.5. Argentina: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 10.7.9. GLP-1 Market – Rest of Latin America
- 10.7.9.1. Rest of Latin America: GLP-1 Market, By Type of Molecule, 2020-2034 (USD Billion)
- 10.7.9.2. Rest of Latin America: GLP-1 Market, By Active Compound Used, 2020-2034 (USD Billion)
- 10.7.9.3. Rest of Latin America: GLP-1 Market, by Type of GLP-1 Agonist Drugs, 2020-2034 (USD Billion)
- 10.7.9.4. Rest of Latin America: GLP-1 Market, by Route of Administration, 2020-2034 (USD Billion)
- 10.7.9.5. Rest of Latin America: GLP-1 Market, by Target Indication, 2020-2034 (USD Billion)
- 11. Competitive Landscape
- 11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
- 11.2. Partnerships/Collaborations/Agreements/Exhibitions
- 12. Company Profiles
- 12.1. AstraZeneca
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
- 12.2. Boehringer Ingelheim
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
- 12.3. D&D Pharmatech
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
- 12.4. Eli Lilly
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
- 12.5. Hanmi Pharmaceutical
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
- 12.6. Novo Nordisk
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
- 12.7. Pfizer
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
- 12.8. Roche
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
- 12.9. Sanofi
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development
- 12.10. Tonghua Dongbao Pharmaceutical
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Benchmarking
- 12.10.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
